Guanfacine treatment of cognitive impairment in schizophrenia

Neuropsychopharmacology

Volumn 25, Issue 3, 2001, Pages 402-409

  Friedman, Joseph I ^a,b,c   Adler, David N ^b   Temporini, Humberto D ^a   Kemether, Eileen ^a   Harvey, Philip D ^a   White, Leonard ^a,b   Parrella, Michael ^b   Davis, Kenneth L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Pilgrim Psychiatric Center   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

Clinical Trial; Cognitive; Guanfacine; Norepinephrine; Schizophrenia

Indexed keywords

ADJUVANT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GUANFACINE; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; MENTAL TASK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCHIZOPHRENIA; SPATIAL MEMORY; STATISTICAL ANALYSIS; TASK PERFORMANCE; TREATMENT OUTCOME; WORKING MEMORY;

ADRENERGIC ALPHA-AGONISTS; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GUANFACINE; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034887916     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00249-4     Document Type: Article

References (50)

1. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology
2. Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity
3. Catecholamine modulation of prefrontal cortical cognitive function
4. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes
5. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys
6. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function potential significance for attention-deficit hyperactivity disorder
7. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged non-human primates
8. The alpha-2a-adrenoreceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task
9. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: IV. Further evidence for regional and behavioral specificity
10. Postmortem central catecholamines and ante mortem cognitive impairment in elderly schizophrenics and controls
11. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys
12. Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography
13. Noradrenergic control of thalamic oscillation: The role of alpha-2 receptors
14. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients
15. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation
16. Guanfacine treatment of comorbid attention deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience
17. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients
18. Dopamine in schizophrenia: A review and reconceptualization
19. Clonidine improves memory function in schizophrenia independently from changes in psychosis: Preliminary findings
20. Visuospatial working memory in patients with schizophrenia
21. The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease
22. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex
23. Regional and cellular fractionation of working memory
24. Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory
25. Circuitry of the primate prefrontal cortex and the regulation of behavior by representational memory
26. The anatomy of dopamine in monkey and human prefrontal cortex
27. Does risperidone improve verbal working memory in treatment resistant schizophrenia?
28. An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder
29. Guanfacine and clonidine, alpha-2 agonists, improve paired associates learning, but not delayed matching to sample, in humans
30. Neuropsychological correlates of central monoamine function chronic schizophrenia: Relationship between CSF metabolites and cognitive function
31. Cloning and sequencing, and expression of the gene coding for the human platelet alpha-2 adrenergic receptor
32. Expansion of the a-2 adrenergic family: Cloning and characterization of human a-2 adrenergic subtype, the gene for which is located on chromosome 2
33. Cognitive enhancement in Korsakoff's psychosis by clonidine: A comparison with L-Dopa and ephedrine
34. Pharmacological evaluation of spatial memory in schizophrenia
35. Clonidine infusion increases uptake of 99mTc-Exametazime in anterior cingulate cortex in Korsakoff's psychosis
36. Distribution of mRNA's for a-2 adrenergic receptor subtypes in rat brain: An in situ hybridization study
37. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
38. Schizophrenics show spatial working memory deficits
39. Cloning and expression of a human kidney cDNA for an a-2 adrenergic receptor subtype
40. Validation of reaction time in continuous performance tasks as an index of attention by electrophysiological measures
41. Brain stem catecholamine mechanisms in tonic and reflex control of blood pressure
42. Distribution of a-2 adrenergic receptor subtype gene expression in rat brain
43. A rating scale for extrapyramidal side effects
44. The effects of guanfacine, alpha-2 agonist, on the performance of young and aged rats in spatial navigation task
45. The alpha-2A noradrenergic agonist, guanfacine, improves visual object discrimination reversal performance in rhesus monkeys
46. Comparison of the binding activities of some drugs on a-2A, A-2B, a-2C adrenoreceptors in noradrenergic imidazoline sites in the guinea pig
47. Decreased frontal activation in schizophrenics during stimulation with the continuous performance test-afunctional magnetic resonance imaging study